Phase 2 dose-ranging study of the virologic efficacy and safety of the combination COVID-19 antibodies casirivimab and imdevimab in the outpatient setting

C Portal-Celhay, E Forleo-Neto, W Eagan, BJ Musser… - medRxiv, 2021 - medrxiv.org
Background The monoclonal antibody combination casirivimab and imdevimab (REGEN-
COV®) reduced viral load, hospitalisation, or death when administered 1: 1 as an …
被引用次数：12 相关文章
[HTML] europepmc.org

[HTML][HTML] Phase 2 dose-ranging study of the virologic efficacy and safety of the combination COVID-19 antibodies casirivimab and imdevimab in the outpatient setting

C Portal-Celhay, E Forleo-Neto, W Eagan, BJ Musser… - 2021 - europepmc.org
Background The monoclonal antibody combination casirivimab and imdevimab (REGEN-
COV®) reduced viral load, hospitalisation, or death when administered 1: 1 as an …